Dupilmuab for Atopic Dermatitis Monitored With Noninvasive Imaging.

  • End date
    Mar 1, 2024
  • participants needed
  • sponsor
    OptiSkin Medical
Updated on 12 March 2022


The study is trying to answer the following question: "Can we use non-invasive imaging to evaluate the response of atopic dermatitis (eczema) to Dupixent (dupilumab)?"


Participating in this research will allow the subject to undergo a noninvasive imaging alternative to conventional monitoring in response to a biologic. Normally, subjects would undergo a clinical examination, serial photography, and possible biopsies to assess the progression of the disease. This study will get rid of the need for a biopsy but will require multiple scans with non-invasive imaging. This research examines a new approach to monitoring response to a biologic drug used for atopic dermatitis, and can also, be used to grade disease severity without the need for a biopsy.

Condition Eczema, Atopic Dermatitis
Treatment Optical Coherence Tomography, Reflectance confocal microscopy, Dupilumab
Clinical Study IdentifierNCT05265234
SponsorOptiSkin Medical
Last Modified on12 March 2022


Yes No Not Sure

Inclusion Criteria

≥18 years of age
Atopic dermatitis (AD) affecting ≥10% body surface area (BSA) at baseline
IGA score ≥3, on the IGA scale of 0-4 at baseline
Eczema Area and Severity Index (EASI) score of ≥16 at baseline

Exclusion Criteria

Prior treatment with Dupilumab (REGN668/SAR231893)
Treatment with TCS or topical calcineurin inhibitors (TCI) within 2 weeks before the baseline visit
Bodyweight <30 kg (65lb) at Baseline
Known or suspected immunodeficiency including human immunodeficiency virus (HIV) infection
Pregnancy, breastfeeding or planning to become pregnant or breastfeed during the study
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note